Taking together our results and those from the literature, a small subgroup of ER+/HER2− breast cancer could potentially benefit from immunotherapy, currently approved for metastatic triple-negative breast cancer and having been tested in other subsets (48–50). Here, ESR1 is linked to triple-negative breast carcinoma.